Nanobiotix (NASDAQ:NBTX) Sets New 52-Week High – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $42.50 and last traded at $41.86, with a volume of 127920 shares traded. The stock had previously closed at $34.77.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NBTX. Guggenheim increased their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. UBS Group lifted their price objective on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.67.

Nanobiotix Stock Performance

The company’s fifty day moving average price is $32.58 and its two-hundred day moving average price is $25.53.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $3.42 million for the quarter. Equities research analysts forecast that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current year.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of Nanobiotix during the third quarter worth $101,000. Marshall Wace LLP bought a new position in shares of Nanobiotix in the 4th quarter valued at $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix during the 4th quarter valued at $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.